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Purpose: Family history is associated with gliomas, but this association has not been
establishedforbenignbraintumors.Usinginformationfromnewlydiagnosedprimarybrain
tumorpatients,wedescribepatternsoffamilycancerhistoriesinpatientswithbenignbrain
tumors and compare those to patients with gliomas. Methods: Newly diagnosed primary
braintumorpatientswereidentiﬁedaspartoftheOhioBrainTumorStudy.Eachpatientwas
asked to participate in a telephone interview about personal medical history, family history
ofcancer,andotherexposures.Informationwasavailablefrom33acousticneuroma(65%),
78 meningioma (65%), 49 pituitary adenoma (73.1%), and 152 glioma patients (58.2%).
The association between family history of cancer and each subtype was compared with
gliomas using unconditional logistic regression models generating odds ratios (ORs) and
95% conﬁdence intervals. Results:There was no signiﬁcant difference in family history of
cancer between patients with glioma and benign subtypes. Conclusion:The results sug-
gest that benign brain tumor may have an association with family history of cancer. More
studies are warranted to disentangle the potential genetic and/or environmental causes
for these diseases.
Keywords: meningioma, acoustic neuroma, pituitary tumor, glioma, family history of cancer
INTRODUCTION
The overall incidence of benign and malignant brain tumors is
18.71 per 100,000 person years; 11.52 per 100,000 person years
for benign tumors; and 7.19 per 100,000 person years for malig-
nant tumors (CBTRUS, 2010). The most common benign brain
tumor in adults is meningioma, followed by pituitary adenoma,
and acoustic neuroma (also called schwannoma). A small pro-
portion of meningiomas (6–8%) are World Health Organization
(WHO) grade II or grade III (Wrobel et al., 2005). Otherwise,
all benign tumors are considered to be WHO grade I. The most
common primary malignant brain tumors are gliomas, the most
common of which is glioblastoma multiforme (GBM), a WHO
g r a d eI Vt u m o r( CBTRUS, 2010).
The only established environmental risk factor for gliomas and
meningiomas is ionizing radiation exposure to the head and neck;
allergies have been inversely associated with glioma risk (Wren-
sch et al., 2002; Ohgaki and Kleihues, 2005; Barnholtz-Sloan and
Kruchko, 2007; Bondy et al., 2008). Inherited syndromes such as
neuroﬁbromatosis 1 and 2, tuberous sclerosis, Li-Fraumeni syn-
drome, and Turcot syndrome can also increase one’s and one’s
familymembers’riskforbothmalignantandbenignbraintumors
aswellasforothercancers(LouisandvonDeimling,1995;Malmer
etal.,2005).Inaddition,multiplestudieshaveshownanincreased
riskof braintumorsandothercancersforfamilymembersof spo-
radic glioma or meningioma patients (Hemminki et al.,2001;Hill
et al., 2003, 2004).
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While many studies have established an association between
family history of cancer and glioma,few have assessed patterns of
family history of cancer in benign brain tumor subtypes (Bondy
et al., 2008; McCarthy et al., 2011). The relationship between
glioma and family history of cancer has been explored by several
investigators, and family history of malignancy has been estab-
lished as a risk factor for gliomas (Hemminki et al., 2000, 2001,
2007; Hemminki and Li, 2004). The studies that have looked into
benign brain tumor subtypes primarily focus on meningioma
and/oracousticneuromaonly,andwhilesomehaveshownsignif-
icant associations between family history of cancer and increased
odds of a brain tumor, others have shown no association (Sakas
et al., 1994; Louis and von Deimling, 1995; Maxwell et al., 1998;
Hemminki et al.,2000,2001; King and Gutmann,2000; Hill et al.,
2003, 2004; Malmer et al., 2003; Bacci et al.,2010).
While studies have utilized large databases to assess family his-
tory of cancer as a potential risk factor for some benign brain
tumor types, most have just examined family history of speciﬁc
cancertypes,suchasbraintumorsorothercentralnervoussystem
tumors. No prior studies could be identiﬁed that examine differ-
ences in family history of cancer between benign primary brain
tumors and gliomas. No previous study has established family
history of cancer as a risk factor for benin brain tumors, though
they have suggested associations between benign brain tumors
and some speciﬁc cancer types. Because a family history of malig-
nancy has been previously established as a risk factor for gliomas
(Hemminki et al., 2000, 2001, 2007; Hemminki and Li, 2004) our
study uses a group of patients with glioma as a reference group to
establish whether family history of cancer may be associated with
benign brain tumor types, using information from newly diag-
nosed primary brain tumor patients enrolled in a multi-site study
within Ohio.
MATERIALS AND METHODS
THE OHIO BRAIN TUMOR STUDY
The Ohio Brain Tumor Study (OBTS) is a multi-site study in
Ohio that prospectively accrues newly diagnosed,untreated brain
tumor patients. This network is comprised of four major acade-
mic brain tumor centers in the state of Ohio: The Brain Tumor
andNeuro-OncologyCenteratUniversityHospitalsCaseMedical
Center(UHCMC)theclinicalafﬁliateof theCaseWesternReserve
University (CWRU) School of Medicine, the Rose Ella Burkhardt
Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic
(CC), The Dardinger Neuro-Oncology Center, Department of
Neurosurgery at the James Cancer Hospital and the Ohio State
University Medical Center (OSU) and the Brain Tumor Center
at the University of Cincinnati (UC). All newly diagnosed pri-
marybraintumorpatientsareidentiﬁedateachcenterbyresearch
nurses,and informed consent is obtained. Patients that have been
diagnosed with a familial cancer syndrome are excluded. From
eachthefollowingareobtained:bloodsample,snap-frozentumor
tissue within 30min of resection, and/or re-cuts of formalin-
ﬁxed,parafﬁnembedded(FFPE)tumortissue(forhistopathology
review), interview/questionnaire data, medical chart review, and
active yearly follow-up for clinical outcomes. All sites have their
own IRB approvals and use the same standardized study protocol,
procedures, and informed consent. In addition each OBTS site
has a fully executed Research/Material Transfer Agreement with
CWRU.
QUESTIONNAIRE AND VARIABLES OF INTEREST
Each subject is asked to take part in a telephone interview last-
ing 30–45min. The interview uses a standardized questionnaire
for all patients that includes questions regarding subjects’ med-
ical history, family history of cancer, medication history, tobacco
use, and other environmental exposure history (potential expo-
sures they may have been exposed to during work or hobbies).All
patients are administered the same questionnaire, and all ques-
tionnaire interviews for all sites are performed by the CWRU
research staff. If the patient is unable to complete the question-
naire, a proxy is allowed to complete the interview. To limit recall
bias,interviews are conducted shortly after completion of surgery
and neoadjuvant treatment. Clinical variables, such as type of
tumor (meningioma, acoustic neuroma, pituitary, astrocytoma,
oligodendroglioma,oligoastrocytoma),andWHOgradeof tumor
(I,II,III,IV),were abstracted from patient medical records. Fam-
ily history of cancer information was not conﬁrmed via clinical
records.
The questionnaires are constructed to elicit the following vari-
ables of interest: age at diagnosis, gender, and detailed family
historyof cancer.Duetosmallsamplesizesof oligodendrogliomas
and oligoastrocytomas, these subtypes were grouped with astro-
cytomas into“gliomas”for analysis,and due to small sample sizes
of atypical and anaplastic meningiomas, i.e., grade II and III, all
meningiomaswereanalyzedtogetherasasinglegroup.Familyhis-
toryof cancerwascodedasafourlevelvariable:none,ﬁrst-degree
only,second-degreeonly,andﬁrstandsecond-degree.Thetypeof
relative and type of cancer that the relative had were also recorded
for all relatives.
STATISTICAL ANALYSIS
Frequency and proportions were calculated for all variables of
interest and categorized by tumor subtypes. Chi-square and
Fisher’s exact tests were used to test for differences in key vari-
ablesofinterestwithineachsubtypeclassiﬁcation.Theassociation
between family history of cancer (none,ﬁrst-degree only,second-
degree only, and ﬁrst and second-degree, and by speciﬁc cancer
types)andeachbenignsubtypeascomparedtogliomaswasmod-
eled using an unconditional logistic regression model generating
odds ratios (ORs) and 95% conﬁdence intervals (95% CI). Logis-
tic regression models were compared to the Base model, which
included the adjustment factors only, using a likelihood ratio test
(LRT) generating a two-sided p-value.
RESULTS
Initially,494 subjects that met histological criteria were consented
for OBTS and follow-up interviews were completed with 312
(63.2% overall; Table 1). The highest proportion of interviews
were obtained from patients with pituitary tumors (73.1% over-
all).Themajorityof benignbraintumorpatientswerefemale,and
had an average age at diagnosis of 54years. Interestingly,20.5% of
patients with meningiomas and 22.4% of patients with pituitary
tumors were non-white as compared to 0% of acoustic neuroma
patients (Fisher’s exact p-value=0.004; Table 1). Eighty-six per-
centof meningiomasweregradeItumors.Themajorityof glioma
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Table 1 | Characteristics of OBTS study population.
Benign subtypes Gliomas
Meningioma Acoustic
neuroma
Pituitary
adenoma
p-Valuea Astrocytoma Oligo-
dendroglioma
Oligo-
astrocytoma
p-Valueb
Total consented 120 46 67 223 27 11
Total interviewedc 78 65.0% 33 71.7% 49 73.1% 131 58.7% 16 59.3% 5 45.5%
Interview type Proband 76 97 .44% 32 96.97% 49 100.0% 96 73.28% 16 100.0% 4 80%
Proxy 2 2.66% 1 3.03% 0 0.0% 35 26.72% 0 0.0% 1 20%
Gender Male 27 34.6% 17 51.5% 22 44.9% 0.2101 77 58.8% 12 75.0% 2 40.0% 0.3321d
Female 51 65.4% 16 48.5% 27 55.1% 54 41.2% 4 25.0% 3 60.0%
Race White 62 79.5% 33 100% 38 77 .6% 0.0039d 120 91.6% 15 93.8% 5 100.0% 1.0000d
Black/other 16 20.5% 0 0% 11 22.4% 11 8.4% 1 6.3% 0 0.0%
Mean age at diagnosis
(minimum, maximum)
55 (22–85) 53 (31–75) 53 (29–75) 57 (20–92) 43 (28–66) 47 (19–65)
Histology Grade I 67 85.9% 33 100.0% 0 0.0% 1 0.8% 0 0.0% 0 0.0%
Grade II 10 12.8% 0 0.0% 0 0.0% 10 7 .6% 9 56.3% 3 60.0%
Grade III 1 1.3% 0 0.0% 0 0.0% 13 9.9% 6 37 .5% 2 40.0%
Grade IV 0 0.0% 0 0.0% 0 0.0% 105 80.2% 0 0.0% 0 0.0%
No grade 0 0.0% 0 0.0% 49 100.0% 0 0.0% 0 0.0% 0 0.0%
aMeasures signiﬁcance of difference between the benign brain tumor subtypes for distribution of this variable.
bMeasures signiﬁcance of difference between the glial brain tumor subtypes for distribution of this variable.
cSome participants declined to provide family history.This population is used for calculating the percentages in the rest of the table.
dFisher’s exact test.
patients were male, white, and had an average age at diagnosis of
55.2years (Table 1). The majority of gliomas were glioblastomas
(Table 1).
Of the 312 patients interviewed, 74.68% reported a ﬁrst or
second-degree family history of cancer (Table 2). Those with
a pituitary adenoma reported the highest proportion of family
history of cancer (81.63%). In comparison, this proportion was
75.64% for the meningiomas, 75.76% for the acoustic neuromas,
and 71.71% for the gliomas (Table 2). Overall, 56% of patients
reported at least one ﬁrst-degree relative with cancer. Proportions
with ﬁrst-degree history of cancer were 58.98% for meningioma
patients, 45.45% for acoustic neuroma patients, 51.02% for pitu-
itary adenoma patients, and 57.89% for glioma patients. Notably,
there are high proportions of colorectal cancers and nervous sys-
tem cancers across all subtypes. Overall,the most common cancer
types in this population’s family members were lung, colorectal,
breast, prostate, and brain.
Comparisons between each of the benign brain tumor types
andgliomasshowedthatforpatientswithbenignsubtypes,thereis
nodifferenceintheoddsof havingaﬁrst-degreeorsecond-degree
relative with cancer. Patients with meningioma had decreased
odds of having a ﬁrst-degree relative with breast cancer compared
to glioma patients after adjustment for age at diagnosis, gender,
family size, and race [OR=0.225, 95% CI (0.059–0.857), LRT
p-value=0.082; Table 3].
DISCUSSION
The population accrued by the OBTS and the subpopulation
includedinthisanalysisaredemographicallysimilartothebroader
US population of brain tumor patients, with our subpopulation
being 50.32% male and 87.5% white (Table 1). The Central Brain
TumorRegistryoftheUS(CBTRUS)was43.11%maleand84.81%
white (CBTRUS, 2010). Of note are the relatively high propor-
tions of non-white meningioma and pituitary patients in the
OBTS population. The CBTRUS data also show a higher inci-
denceof meningiomasandpituitarytumorsandalowerincidence
of gliomas in blacks as we observed in our OBTS study popu-
lation. US population-based data show a female dominance for
meningiomas,as we had in the OBTS study (CBTRUS,2010). The
similarities between the OBTS population and that reported in
CBTRUSsuggestthatbraintumorpatientpopulationsharesmany
demographic characteristics with the United States population
with brain tumor at large.
Theoverallproportionsof familyhistoryof cancerinthispop-
ulationarehighwhencomparedtopreviousstudiesof thegeneral
population(Ramseyetal.,2006)andtheproportionofﬁrst-degree
family history of cancer in this population is comparable to that
found in a hospital-based study of malignant brain tumor patient
populations (Scheurer et al., 2007). Previous registry and case
control studies have found an elevated risk for speciﬁc cancers
particularly nervous system cancers (Hemminki et al.,2000,2001;
Malmeretal.,2003),orfamilyhistoryofcancerinﬁrst-degreerela-
tivesofpersonswithmeningioma(Hilletal.,2004).Afamilystudy
conductedbySakasetal.(1994)foundnosigniﬁcantdifferencein
familyhistoryofcancerbetweenpersonswithbenignormalignant
brain neoplasms and healthy controls. Our population reported
relatively high rates of nervous system cancers in ﬁrst and second-
degree relatives,compared to previous studies that have suggested
elevated standard incidence ratios for nervous systems in ﬁrst-
degree family members of persons with meningioma (Hemminki
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T a b l e2|O v e r a l la n ds i t e-speciﬁc family history of cancer by brain tumor histologic type.
Cancer site Degree of relative
with cancer
Meningioma
(n =78)
Acoustic neuroma
(n =33)
Pituitaryadenoma
(n =49)
All gliomas
(n =152)
Overall None 19 24.36% 8 24.24% 9 18.37% 43 28.29%
1˚ 22 28.21% 7 21.21% 13 26.53% 58 38.16%
2˚ 13 16.67% 10 30.30% 15 30.61% 21 13.82%
1˚ and 2˚ 24 30.77% 8 24.24% 12 24.49% 30 19.74%
Breast None 67 85.90% 26 78.79% 34 69.39% 119 78.29%
1˚ 3 3.85% 3 9.09% 6 12.24% 18 11.84%
2˚ 6 7 .69% 4 12.12% 8 16.33% 11 7 .24%
1˚ and 2˚ 2 2.56% 0 0.00% 1 2.04% 4 2.63%
Colon None 65 83.33% 29 87 .88% 40 81.63% 143 94.08%
1˚ 8 10.26% 1 3.03% 2 4.08% 6 3.95%
2˚ 4 5.13% 3 9.09% 6 12.24% 3 1.97%
1˚ and 2˚ 1 1.28% 0 0.00% 1 2.04% 0 0.00%
Prostate None 69 88.46% 28 84.85% 41 83.67% 138 90.79%
1˚ 2 2.56% 4 12.12% 2 4.08% 11 7 .24%
2˚ 7 8.97% 1 3.03% 4 8.16% 3 1.97%
1˚ and 2˚ 0 0.00% 0 0.00% 1 2.04% 0 0.00%
Lung None 59 75.64% 25 75.76% 36 73.47% 116 76.32%
1˚ 9 11.54% 2 6.06% 3 6.12% 24 15.79%
2˚ 9 11.54% 5 15.15% 10 20.41% 12 7 .89%
1˚ and 2˚ 1 1.28% 1 3.03% 0 0.00% 0 0.00%
Brain None 66 84.62% 29 87 .88% 40 81.63% 132 86.84%
1˚ 6 7 .69% 0 0.00% 2 4.08% 13 8.55%
2˚ 6 7 .69% 3 9.09% 7 14.29% 7 4.61%
1˚ and 2˚ 0 0.00% 1 3.03% 0 0.00% 0 0.00%
and Li, 2004). Previous studies have not compared benign brain
tumor populations to brain tumor populations where family his-
tory of cancer is a established risk factor. Previous studies have
largely not examined overall family history of cancer, but rather
have focused on speciﬁc cancer types.
Both case control and registry-based studies have suggested
an association between breast cancer (or a family history of breast
cancer)andeithermeningiomasorpituitaryadenomas(Hilletal.,
2004; Hemminki et al.,2007).We found decreased odds of having
a ﬁrst-degree relative with breast cancer for meningioma patients,
as compared to all glioma patients. Our data do not show that
either pituitary adenoma or acoustic neuroma has a statistically
greater or lesser likelihood of having a relative with breast cancer.
Hemminki et al. (2007) showed an association between patients
with pituitary adenoma and siblings with colorectal and breast
cancer,as well as other tumor types,in a study based on validated
registry data.
TheOBTSaccruesnewlydiagnosedprimarybenignandmalig-
nant brain tumor patients from four large tertiary referral centers
in Ohio. Recruiting from tertiary care centers allows the OBTS to
recruitahigherproportionof highergradeandmalignanttumors,
whilerecruitinglesslowgradeandnon-malignanttumors.Astan-
dardizedprotocolforscreening,patientaccrualanddatacollection
is used at all participating sites. Telephone interviews and medical
chart reviews are done centrally by staff from CWRU, using a
regular study staff that has all completed the same standardized
training to minimize bias. Though the sample size of this analysis
is considerable considering the rarity of brain tumors, the small
sample size results in some instability of the data produced by
the analysis. Previous studies that have examined the relation-
ship between family history and brain tumors have been based
onpopulationsbetween3239and11,875inregistry-basedstudies
(Malmer et al., 2003; Hemminki et al., 2007), 96 in case control
studies (Hill et al., 2004), and 142 in family-based studies (Sakas
et al.,1994). Previous studies examining the relationship between
family history of cancer and glioma have been based on popula-
tions between 462 and 489 in case control studies (Wrensch et al.,
1997; Hill et al., 2003), 20358 in registry-based studies (Malmer
etal.,2003),andbetween639and1476infamily-basedstudies(de
Andradeetal.,2001;Scheureretal.,2007).Thepopulationusedin
thisanalysisisonthelowerendofthisspectrum,butiscomparable
to previous studies. Accrual of additional patients over time will
improve the power to detect associations. A similar analysis with
registry data that contains clinically validated family history data
would also build upon the correlation suggested by this analysis.
Usingpatientswithgliomasasacomparisongrouppresentssig-
niﬁcantlimitationsfortheresultsofthisanalysis.Whileananalysis
using a control group of persons without brain tumor would pro-
duce more generalizable data about risk of benign brain tumor
based on family history of cancer, using a reference group known
to have an increased risk of family history of cancer also provides
an informative comparison. Though this does not establish fam-
ily history of a cancer as a risk factor for benign brain tumors, it
does suggest that there may be some association between the two
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when compared to persons with glioma that are known to have an
increased risk of family history of cancer. Future comparison of
this benign brain tumor population with healthy controls would
provide more information about family history of cancer as a risk
factor for benign brain tumors. Additionally, there may be other
potential factors that may be related to increased family history of
cancer were not included in this analysis.
All of the family history data used in the current analysis were
collected from patient self-report via telephone interview with
a standardized questionnaire, where only 3% of the interviewed
population chose not to answer questions about their family
historyof cancer.Thoughfamilyhistoryinformationwasnotvali-
dated using medical records,previous studies have concluded that
subjects are able to accurately report the cancer history of fam-
ily members without observable bias, but that cancer site-speciﬁc
recall may be less accurate than recall of whether a cancer his-
tory exists (Kerber and Slattery, 1997; Airewele et al., 1998). Even
with cancer site-speciﬁc recall difﬁculties, researchers have found
that ﬁrst-degree relative cancer history is reported at 83% accu-
racy,and second-degree relative cancer history is reported at 67%
(Love et al., 1985). Mai et al. (2011) found that site-speciﬁc recall
maygenerallybelessaccuratethanthis,ﬁndingpositivepredictive
values of 40% for lung cancer, 53.5% for colorectal cancer, 61.3%
for breast cancer, and 53.4% for prostate cancer, with reporting
on ﬁrst-degree relatives being signiﬁcantly more accurate than
second-degree relatives. Thus the information about whether a
family cancer exists collected via the questionnaire is assumed to
be largely accurate, although the site-speciﬁc information may be
less dependable. The study design of the OBTS consorsium does
not currently allow for validation of family cancer history data via
family medical records, though this would improve the validity
generalizability of this analysis. This difference between odds for
ﬁrst-degree versus second-degree relatives may be a result of the
decreased reliability of patient self-report of second-degree rel-
ative cancer history. In addition, the site-speciﬁc ORs may have
occurred by chance due to the lack of reliability of site-speciﬁc
self-report of family history of cancer.
Some patients in the OBTS study died before the interview was
initiated or were otherwise lost to follow-up, and others declined
to participate in the interview after initial consent. Participation
was particularly low among patients with astrocytomas, oligo-
dendrogliomas, and oligoastrocytomas (58.75, 59.3, and 45.5%
interview participation, respectively). We surmise that this might
reﬂect the additional stresses these patients were subjected to due
totheneedforadjuvanttherapiesthatwasuncommonintheother
groups, though this was not quantiﬁed. This may also represent a
survival bias, as persons that died shortly after or during surgery
ortreatmentwereexcludedfromthisanalysis.Mediansurvivalfor
persons with glioma who were not interviewed versus those who
were interviewed was signiﬁcantly different,with median survival
Table 5 | Characteristics of interviewed and non-interviewed patients.
Interviewed Not interviewed p-Value
Male 157 50.32% 93 51.10% 0.8674
White 273 87 .50% 156 85.71% 0.5711
Median age (minimum, maximum) 55 (19, 92) 56 (21, 86) 0.5111
Mean survival (95% CI; days) All gliomas 190 (152–307) 523 (406–689) <0.001
Histologic type Acoustic neuroma 33 100% 13 100%
Meningioma
Grade I 67 85.90% 25 64.10% 0.0067
Grade II–III 11 14.10% 14 35.90%
Pituitary adenoma 49 100% 18 100%
Astrocytoma 0.6345a
Grade I 1 0.78% 2 2.22%
Grade II 10 7 .75% 10 11.11%
Grade III 13 10.08% 7 7 .78%
Grade IV 105 81.40% 71 78.89%
Oligoastrocytoma 1.0000a
Grade II 3 60.00% 4 66.67%
Grade III 2 40.00% 2 33.33%
Oligodendroglioma 0.3945a
Grade II 9 60.00% 9 81.82%
Grade III 6 40.00% 2 18.18%
Grade No grade 49 15.86% 18 10.17% 0.0047
Grade I 101 32.69% 40 22.60%
Grade II 32 10.36% 35 19.77%
Grade III 22 7 .12% 13 7 .34%
Grade IV 105 33.98% 71 40.11%
aFisher exact test.
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of 190days (95% CI 152–307) and 523days (95% CI 406–689)
respectively (p <0.001). Overall, our response rate was very good
when compared to other survey or questionnaire-based studies.
A particular strength is the structured interview, which may have
allowed us to better elicit family history data.
Whenapatientwasunabletocompletethetelephoneinterview,
a proxy was allowed to complete the interview on behalf of that
patient. Rates of proxy interview were relatively low in the benign
tumor types (3.03% for acoustic neuromas, 2.66% for menin-
giomas,and0%forpituitarytumors;Table 1).Inthegliomatypes,
rates were higher,particularly in the astrocytomas and oligoastro-
cytomas(ratesofproxyinterviewwere26.72and20%respectively;
Table 1). When these proxy interviews were excluded from the
analysis, the effects detected in the overall comparison remained
(Table 4).
The population that consented to the study but did not partic-
ipate in the interview had no statistically signiﬁcant difference in
gender,race,or age,with the population that completed the inter-
view (Table 5). However, among meningioma patients, the un-
interviewed population had a signiﬁcantly increased proportion
of higher grade tumors (14.10% grade II or III in the interviewed
populationand35.90%gradeIIorIIIintheun-interviewedpopu-
lation,p =0.0067; Table 2). There was no signiﬁcant difference in
theproportionofgradesintheastrocytoma(81.4%gradeIVinthe
interviewedpopulationand78.9%gradeIVintheun-interviewed
population),oligodendroglioma(40%gradeIIIintheinterviewed
population and 33.39% grade III in the un-interviewed popu-
lation), or oligoastrocytoma (40% grade III in the interviewed
population and 18.9% grade III in the un-interviewed popu-
lation) patients (Table 5). As this study involves patients who
may be very ill and have signiﬁcant neurocognitive problems, an
overall interview rate of 63.16% is considered high. Because of
the small sample size of atypical meningiomas, all meningiomas
were grouped together for analysis. In addition, all gliomas were
grouped together for analysis regardless of subtype because of the
small number of non-astrocytic gliomas. Therefore, our menin-
gioma results could be biased toward grade I meningiomas and
ourgliomaresultscouldbebiasedtowardglioblastomas.Glioblas-
tomaonlycomparisonsstillshowedsigniﬁcantlyincreasedoddsof
patients with pituitary adenomas having a second-degree relative
with cancer.
In conclusion,the odds of having a ﬁrst or second-degree rela-
tive with cancer are not signiﬁcantly different between patients
with benign tumors and patients with gliomas. As previous
research has established an association between family history of
cancer and gliomas, this suggests that it may also be associated
with benign brain tumors. Previous research has not established
family history of cancer as a risk factor for benign brain tumors,
and have produced some conﬂicting results. Our study and others
suggest that more family studies of brain tumor subtypes are war-
ranted to disentangle the potential genetic and/or environmental
causes for familial occurrence of these neoplasms.
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